{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-028987","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.573122+00:00","generated_at":"2026-06-22T02:48:50.575921+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cumberland Q3 revenue up 41% to $11.4M; net loss narrows to $0.4M","bullets":["Net revenue $11.4M vs $8.1M a year ago, driven by Sancuso ($4.0M) and Kristalose ($3.9M).","Net loss improved to $0.4M from $1.1M; adjusted earnings $1.4M ($0.10/share).","Year-to-date cash from operations $5.6M, up 28% from $4.4M.","Completed Sancuso transition under co-promotion with Verity; RediTrex amendment allows Nordic to assume U.S. commercialization after March 2023.","Phase II ifetroban trials ongoing; AERD study closed to enrollment awaiting top-line results."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-028987","json":"https://secwatch.observer/filing/0001628280-22-028987.json","markdown":"https://secwatch.observer/filing/0001628280-22-028987.md","text":"https://secwatch.observer/filing/0001628280-22-028987.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000162828022028987/0001628280-22-028987-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000162828022028987/cpix-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T02:48:50.575921+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"97b6b272ecbb6deb6806323123cca41ab70f1e2a","claim":"CUMBERLAND PHARMACEUTICALS INC reported the three months ended September 30, 2022 results: revenue $11.4 million, net income Net loss for the third quarter of 2022 was $0.4 million.","evidence_excerpt":"Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined revenues of $11.4 million during the third quarter of 2022 - a 41% increase over the prior year period. Cumberland also reported a 19% increase in net revenues for the first nine months of the year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1087294/000162828022028987/0001628280-22-028987-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2022"},{"label":"Revenue","value":"$11.4 million"},{"label":"Net income","value":"Net loss for the third quarter of 2022 was $0.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b7d8c83a280b78c79174352bea2cfd604710e566","claim":"CUMBERLAND PHARMACEUTICALS INC reported the nine months ended September 30, 2022 results: revenue $33 million.","evidence_excerpt":"of 2022, included $4.0 million for Sancuso ® , $3.9 million for Kristalose ® , $1.9 million for Vibativ ® and $0.9 million for Caldolor ® . Year-to-date 2022 net revenues were $33 million, a 19% increase compared to $28 million for the first nine months of 2021. Year-to-date net revenues by product were $11.4 million for Kristalose, $10.8 million for Sancuso, $6.0","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1087294/000162828022028987/0001628280-22-028987-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the nine months ended September 30, 2022"},{"label":"Revenue","value":"$33 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}